—Symposium Reviews— |
|
Forefront Researches of Drug Innovation Technology in the Post-genomic Era—Studies of Biomarker Discovery for Drug Development— |
| ………
K. Nagano, H. Nabeshi, and S. Tsunoda |
…463 |
|
Safety Assessment of Nanomaterials Using Toxicokinetics and Toxicoproteome Analysis |
| ………
H. Nabeshi, T. Yoshikawa, T. Imazawa, S. Tsunoda, and Y. Tsutsumi |
…465 |
|
New Functional Proteins Identified by Proteomic Analysis in the Epidermal Growth Factor Receptor-mediated Signaling Pathway and Application for Practical Use |
| ………
K. Tashiro, H. Konishi, H. Nabeshi, E. Yamauchi, and H. Taniguchi |
…471 |
|
Development of Anti-tumor Blood Vessel Antibodies by Phage Display Method |
| ………
T. Yamashita, N. Utoguchi, R. Suzuki, K. Nagano, S. Tsunoda, Y. Tsutsumi, and K. Maruyama |
…479 |
|
From Disease Proteomics to Biomarker Development—Establishment of Antibody Proteomics Technology and Exploration of Cancer-related Biomarkers— |
| ………
K. Nagano, S. Imai, S. Nakagawa, S. Tsunoda, and Y. Tsutsumi |
…487 |
|
Elucidation of Mechanism Underlying Amyloid-β Peptide Aggregation and Its Neurotoxicity Expression and Inhibition of These Molecular Processes by Beneficial Synthetic and Natural Compounds with Low-molecular Weights—New Approaches to Fundamental Treatment and Prevention of Alzheimer's Disease— |
| ………
T. Yamakuni |
…493 |
|
Conformational Regulation of Amyloid β-peptide by Lipid Membranes and Metal Ions |
| ………
T. Miura, M. Yoda, C. Tsutsumi, K. Murayama, and H. Takeuchi |
…495 |
|
A Search for Antiamyloidogenic Compounds Based on a Nucleation-Dependent Polymerization Model |
| ………
H. Naiki, K. Hasegawa, K. Ono, and M. Yamada |
…503 |
|
Ganglioside Cluster-mediated Aggregation and Cytotoxicity of Amyloid β-Peptide: Molecular Mechanism and Inhibition |
| ………
K. Matsuzaki |
…511 |
|
Preventive Action of Nobiletin, a Constituent of AURANTII NOBILIS PERICARPIUM with Anti-dementia Activity, against Amyloid-β Peptide-induced Neurotoxicity Expression and Memory Impairment |
| ………
T. Yamakuni, A. Nakajima, and Y. Ohizumi |
…517 |
|
Development of Anti-Alzheimer's Disease Drug Based on Beta-Amyloid Hypothesis |
| ………
H. Sugimoto |
…521 |
|
Development of Novel Cell Culture Systems and Their Application to Pharmaceutical Research |
| ………
A. Taniguchi and T. Takezawa |
…527 |
|
Development of Novel Culture System Using Nano-biotechnology |
| ………
A. Taniguchi, K. Wada, and M. Ohno |
…529 |
|
Development of Novel Culture System for Regulation of Hepatocyte Function |
| ………
K. Yagi, M. Kawase, K. Isoda, and M. Kondoh |
…537 |
|
On-chip Cellomics Technology for Drug Screening System Using Cardiomyocyte Cells from Human Stem Cell |
| ………
K. Yasuda |
…545 |
|
Cellular Engineering and Biosensor Technology for High Through-put Analysis on Drug Discovery |
| ………
T. Haruyama |
…559 |
|
Development of Novel Cell Culture Systems Utilizing the Advantages of Collagen Vitrigel Membrane |
| ………
T. Takezawa, M. Fukuda, W. Mcintosh-Ambrose, J.-A. Ko, J. Elisseeff, S. Haga, M. Ozaki, K. Kato, P.-C. Wang, T. Uchino, and T. Nishida |
…565 |
|
Pharmaceutical Science in Acute Care that Requires Clinical Sense |
| ………
K. Ooi and N. Takamura |
…575 |
|
The Roles of Pharmacists in Cardiopulmonary Resuscitation (CPR) |
| ………
H. Kawara, Y. Tokuyama, and Y. Shimizu |
…577 |
|
Life-support Training to Improve the Clinical Competence of Pharmacy Students |
| ………
N. Takamura, J. Tokunaga, K. Ogata, H. Yoshida, and N. Setoguchi |
…583 |
|
Possible Role of Pharmacists in Emergency Medical Care |
| ………
T. Takeda |
…589 |
—Regular Articles— |
|
Cost-effectiveness of Salmeterol/Fluticasone Combination Therapy vs. Fluticasone Propionate in Japanese Asthmatic Patients |
| ………
Y. Tohda, S. Nishima, I. Arakawa, M. Shiragami, and T. Miyamoto |
…593 |
|
Proposition and Evaluation of the Educational Activities for Effective Utilization of Opioids Performed by Pharmacists in Palliative Home Care |
| ………
N. Akai, D. Hashimoto, T. Fujita, K. Miyake, W. Hamabe-Fujita, and S. Tokuyama |
…605 |
|
Estimating Pediatric Doses of Drugs Metabolized by Cytochrome P450 (CYP) Isozymes, Based on Physiological Liver Development and Serum Protein Levels |
| ………
S. Suzuki, Y. Murayama, E. Sugiyama, V. Hirunpanich, K. Saito, M. Sekiyama, and H. Sato |
…613 |
—Articles— |
|
The Optimal Volume of Medicinal Solution in the Portable Disposable Infusion Pump (SUREFUSER®A) for FOLFOX6, FOLFIRI Therapy of Colorectal Cancer Patients (2nd Report) - Influence of Temperature on Outflow Speed of the Medicinal Solution |
| ………
Y. Kawabata and A. Nakagawa |
…621 |